Skip to main content

Sangamo Therapeutics, Inc

SGMOQ
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001001233

No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.

Holders of 5% or more of SGMOQ

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Sangamo Therapeutics, Inc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of SGMOQ
HolderLatest formStakeChangeFirst filedLatest filingFiling
Armistice Capital, LLC13G/A9.38%38.9M shares−0.37 ppfrom 9.75%May 15, 20262 filingsAug 14, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

27 Schedule 13D and 13G filings on Sangamo Therapeutics, Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on SGMOQ
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 202610:26 AM ETArmistice Capital, LLCand 1 other13G/A9.38%38.9M shares−0.37 ppfrom 9.75%Jun 30, 2026SEC
May 15, 202611:27 AM ETArmistice Capital, LLCand 1 other13G9.75%40.4M sharesNewMar 31, 2026SEC
Nov 12, 20252:34 PM ETWasatch Advisors Inc13G/A2.10%6.19M shares−3.10 ppfrom 5.20%Below 5%Sep 30, 2025SEC
May 12, 20255:32 PM ETWasatch Advisors Inc13G/A5.20%11.6M shares−1.40 ppfrom 6.60%Mar 31, 2025SEC
Jan 7, 20256:47 PM ETWasatch Advisors Inc13G/A6.60%14.0M shares–Dec 31, 2024SEC
Nov 12, 2024Vanguard Group Inc13G/AOld format–––SEC
Nov 4, 2024Vanguard Group Inc13G/AOld format–––SEC
Aug 16, 20246:40 PM ETBiogen Inc.13G/AOld format–––SEC
Jul 8, 20244:32 PM ETBlackRock Inc.13G/AOld format–––SEC
Apr 5, 2024Wasatch Advisors Inc13G/AOld format–––SEC
Feb 13, 2024Vanguard Group Inc13G/AOld format–––SEC
Feb 12, 20247:11 PM ETBiogen Inc.13G/AOld format–––SEC
Feb 9, 2024Wasatch Advisors Inc13G/AOld format–––SEC
Jan 26, 202411:49 AM ETBlackRock Inc.13G/AOld format–––SEC
Jan 22, 2024State Street Corp13G/AOld format–––SEC
Oct 10, 2023Wasatch Advisors Inc13G/AOld format–––SEC
Feb 9, 2023Vanguard Group Inc13G/AOld format–––SEC
Feb 9, 2023Wasatch Advisors Inc13G/AOld format–––SEC
Feb 7, 2023State Street Corp13G/AOld format–––SEC
Jan 24, 20231:56 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 11, 2022Wasatch Advisors Inc13G/AOld format–––SEC
Feb 10, 2022Vanguard Group Inc13G/AOld format–––SEC
Feb 1, 20225:08 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 11, 2021Wasatch Advisors Inc13G/AOld format–––SEC
Feb 10, 2021Vanguard Group Inc13G/AOld format–––SEC
Feb 4, 2021Wellington Management Group LLP13G/AOld format–––SEC
Feb 1, 20218:23 AM ETBlackRock Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Sangamo Therapeutics, Inc shares.

No Form 144 notices for Sangamo Therapeutics, Inc are on file.